Skip to main content
NCBI home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1994 Jul 1;180(1):377–382. doi: 10.1084/jem.180.1.377

Tumor necrosis factor alpha-induced angiogenesis depends on in situ platelet-activating factor biosynthesis

PMCID: PMC2191549  PMID: 7516414

Abstract

Tumor necrosis factor (TNF) alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Therefore, it was suggested that the angiogenic properties of this agent might be consequent to the production of secondary mediators. Since TNF-alpha stimulates the synthesis of platelet-activating factor (PAF) by monocytes and endothelial cells, we investigated the possible involvement of PAF in the angiogenic effect of TNF-alpha. Angiogenesis was studied in a murine model in which Matrigel was used as a vehicle for the delivery of mediators. In this model the angiogenesis induced by TNF-alpha was shown to be inhibited by WEB 2170, a specific PAF receptor antagonist. Moreover, in mice injected with TNF-alpha, PAF was detected within the Matrigel, 6 and 24 h after TNF-alpha injection. The synthesis of PAF within the Matrigel was concomitant with the early migration of endothelial cells and infiltration of monocytes. No infiltration of lymphocytes or polymorphonuclear leukocytes was observed. Synthetic PAF as well as PAF extracted and purified from mice challenged with TNF-alpha induced a rapid angiogenic response, inhibited by WEB 2170. These results suggest that the angiogenic effect of TNF-alpha is, at least in part, mediated by PAF synthesized from monocytes and/or endothelial cells infiltrating the Matrigel plug.

Full Text

The Full Text of this article is available as a PDF (1.0 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Azizkhan R. G., Azizkhan J. C., Zetter B. R., Folkman J. Mast cell heparin stimulates migration of capillary endothelial cells in vitro. J Exp Med. 1980 Oct 1;152(4):931–944. doi: 10.1084/jem.152.4.931. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. BLIGH E. G., DYER W. J. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959 Aug;37(8):911–917. doi: 10.1139/o59-099. [DOI] [PubMed] [Google Scholar]
  3. Bussolino F., Gremo F., Tetta C., Pescarmona G. P., Camussi G. Production of platelet-activating factor by chick retina. J Biol Chem. 1986 Dec 15;261(35):16502–16508. [PubMed] [Google Scholar]
  4. Bussolino F., Pescarmona G., Camussi G., Gremo F. Acetylcholine and dopamine promote the production of platelet activating factor in immature cells of chick embryonic retina. J Neurochem. 1988 Dec;51(6):1755–1759. doi: 10.1111/j.1471-4159.1988.tb01155.x. [DOI] [PubMed] [Google Scholar]
  5. Camussi G., Aglietta M., Malavasi F., Tetta C., Piacibello W., Sanavio F., Bussolino F. The release of platelet-activating factor from human endothelial cells in culture. J Immunol. 1983 Nov;131(5):2397–2403. [PubMed] [Google Scholar]
  6. Camussi G., Bussolino F., Salvidio G., Baglioni C. Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet-activating factor. J Exp Med. 1987 Nov 1;166(5):1390–1404. doi: 10.1084/jem.166.5.1390. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Camussi G., Salvidio G., Niesen N., Brentjens J., Andres G. Effect of chlorpromazine on the development of experimental glomerulonephritis and Arthus reaction. Am J Pathol. 1988 Jun;131(3):418–434. [PMC free article] [PubMed] [Google Scholar]
  8. Camussi G., Tetta C., Baglioni C. The role of platelet-activating factor in inflammation. Clin Immunol Immunopathol. 1990 Dec;57(3):331–338. doi: 10.1016/0090-1229(90)90108-3. [DOI] [PubMed] [Google Scholar]
  9. Camussi G., Turello E., Bussolino F., Baglioni C. Tumor necrosis factor alters cytoskeletal organization and barrier function of endothelial cells. Int Arch Allergy Appl Immunol. 1991;96(1):84–91. doi: 10.1159/000235539. [DOI] [PubMed] [Google Scholar]
  10. Camussi G., Turello E., Tetta C., Bussolino F., Baglioni C. Tumor necrosis factor induces contraction of mesangial cells and alters their cytoskeletons. Kidney Int. 1990 Nov;38(5):795–802. doi: 10.1038/ki.1990.273. [DOI] [PubMed] [Google Scholar]
  11. Dubois C., Bissonnette E., Rola-Pleszczynski M. Platelet-activating factor (PAF) enhances tumor necrosis factor production by alveolar macrophages. Prevention by PAF receptor antagonists and lipoxygenase inhibitors. J Immunol. 1989 Aug 1;143(3):964–970. [PubMed] [Google Scholar]
  12. Folkman J., Klagsbrun M. Angiogenic factors. Science. 1987 Jan 23;235(4787):442–447. doi: 10.1126/science.2432664. [DOI] [PubMed] [Google Scholar]
  13. Fràter-Schröder M., Risau W., Hallmann R., Gautschi P., Böhlen P. Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci U S A. 1987 Aug;84(15):5277–5281. doi: 10.1073/pnas.84.15.5277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Heuer H. O., Casals-Stenzel J., Muacevic G., Weber K. H. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor. J Pharmacol Exp Ther. 1990 Dec;255(3):962–968. [PubMed] [Google Scholar]
  15. Kibbey M. C., Grant D. S., Kleinman H. K. Role of the SIKVAV site of laminin in promotion of angiogenesis and tumor growth: an in vivo Matrigel model. J Natl Cancer Inst. 1992 Nov 4;84(21):1633–1638. doi: 10.1093/jnci/84.21.1633. [DOI] [PubMed] [Google Scholar]
  16. Klagsbrun M., D'Amore P. A. Regulators of angiogenesis. Annu Rev Physiol. 1991;53:217–239. doi: 10.1146/annurev.ph.53.030191.001245. [DOI] [PubMed] [Google Scholar]
  17. Kuijpers T. W., Hakkert B. C., Hart M. H., Roos D. Neutrophil migration across monolayers of cytokine-prestimulated endothelial cells: a role for platelet-activating factor and IL-8. J Cell Biol. 1992 May;117(3):565–572. doi: 10.1083/jcb.117.3.565. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. NACHLAS M. M., SELIGMAN A. M. The histochemical demonstration of esterase. J Natl Cancer Inst. 1949 Apr–Jun;9(5-6):415–425. [PubMed] [Google Scholar]
  19. Nakamura M., Honda Z., Izumi T., Sakanaka C., Mutoh H., Minami M., Bito H., Seyama Y., Matsumoto T., Noma M. Molecular cloning and expression of platelet-activating factor receptor from human leukocytes. J Biol Chem. 1991 Oct 25;266(30):20400–20405. [PubMed] [Google Scholar]
  20. Passaniti A., Taylor R. M., Pili R., Guo Y., Long P. V., Haney J. A., Pauly R. R., Grant D. S., Martin G. R. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest. 1992 Oct;67(4):519–528. [PubMed] [Google Scholar]
  21. Shukla S. D. Platelet-activating factor receptor and signal transduction mechanisms. FASEB J. 1992 Mar;6(6):2296–2301. doi: 10.1096/fasebj.6.6.1312046. [DOI] [PubMed] [Google Scholar]
  22. Silvestro L., Da Col R., Scappaticci E., Libertucci D., Biancone L., Camussi G. Development of a high-performance liquid chromatographic-mass spectrometric technique, with an ionspray interface, for the determination of platelet-activating factor (PAF) and lyso-PAF in biological samples. J Chromatogr. 1993 Sep 24;647(2):261–269. doi: 10.1016/0021-9673(93)83406-i. [DOI] [PubMed] [Google Scholar]
  23. Tessner T. G., O'Flaherty J. T., Wykle R. L. Stimulation of platelet-activating factor synthesis by a nonmetabolizable bioactive analog of platelet-activating factor and influence of arachidonic acid metabolites. J Biol Chem. 1989 Mar 25;264(9):4794–4799. [PubMed] [Google Scholar]
  24. Tracey K. J., Vlassara H., Cerami A. Cachectin/tumour necrosis factor. Lancet. 1989 May 20;1(8647):1122–1126. doi: 10.1016/s0140-6736(89)92394-5. [DOI] [PubMed] [Google Scholar]
  25. Valone F. H., Epstein L. B. Biphasic platelet-activating factor synthesis by human monocytes stimulated with IL-1-beta, tumor necrosis factor, or IFN-gamma. J Immunol. 1988 Dec 1;141(11):3945–3950. [PubMed] [Google Scholar]
  26. Venable M. E., Zimmerman G. A., McIntyre T. M., Prescott S. M. Platelet-activating factor: a phospholipid autacoid with diverse actions. J Lipid Res. 1993 May;34(5):691–702. [PubMed] [Google Scholar]
  27. Voelkel N. F., Worthen S., Reeves J. T., Henson P. M., Murphy R. C. Nonimmunological production of leukotrienes induced by platelet-activating factor. Science. 1982 Oct 15;218(4569):286–289. doi: 10.1126/science.7123233. [DOI] [PubMed] [Google Scholar]
  28. Weber C., Aepfelbacher M., Haag H., Ziegler-Heitbrock H. W., Weber P. C. Tumor necrosis factor induces enhanced responses to platelet-activating factor and differentiation in human monocytic Mono Mac 6 cells. Eur J Immunol. 1993 Apr;23(4):852–859. doi: 10.1002/eji.1830230413. [DOI] [PubMed] [Google Scholar]
  29. Ye R. D., Prossnitz E. R., Zou A. H., Cochrane C. G. Characterization of a human cDNA that encodes a functional receptor for platelet activating factor. Biochem Biophys Res Commun. 1991 Oct 15;180(1):105–111. doi: 10.1016/s0006-291x(05)81261-6. [DOI] [PubMed] [Google Scholar]
  30. Zimmerman G. A., Prescott S. M., McIntyre T. M. Endothelial cell interactions with granulocytes: tethering and signaling molecules. Immunol Today. 1992 Mar;13(3):93–100. doi: 10.1016/0167-5699(92)90149-2. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES